Publications, posters & presentations -
our significant research

The Novavax Heterologous COVID Booster Demonstrates Lower Reactogenicity Than mRNA: A Targeted Review

Immunogenicity and safety of heterologous Omicron BA.1 and bivalent SARS-cov-2 recombinant spike protein booster vaccines: a phase 3, randomized, clinical trial

Biodistribution of the Saponin-Based Adjuvant Matrix-M™ Following Intramuscular Injection in Mice

XBB.1.5 spike protein COVID‑19 vaccine induces broadly neutralizing and cellular immune responses against EG.5.1 and emerging XBB variants

A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Novavax COVID-19 Vaccine (NVX-CoV2373), a recombinant spike protein vaccine with Matrix-M adjuvant to prevent disease caused by SARS-CoV-2 viruses

Risk of COVID-19 after natural infection or vaccination

XBB.1.5 Spike Protein COVID-19 Vaccine Induces Broadly Neutralizing and Cellular Immune Responses Against EG.5.1 and Emerging XBB Variants

Immunogenicity and safety of NVX-CoV2373 as a booster: A phase 3 randomized clinical trial in adults

Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trial

Strong CD4+ T-Cell Responses to Ancestral and Variant Spike Proteins Are Established by NVX-CoV2373 SARS-CoV-2 Primary Vaccination